The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibitionElena Ardini, Antonella Isacchi, Rachele Alzani et al.|Molecular Oncology|2014Cited by 156
Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and BrachyuryPaola Magnaghi, Antonella Isacchi, Barbara Salom et al.|Molecular Cancer Therapeutics|2017Cited by 93
Establishment and genomic characterization of the new chordoma cell line Chor-IN-1Roberta Bosotti, Antonella Isacchi, Paola Magnaghi et al.|Scientific Reports|2017Cited by 17
Cell Line Identity Finding by Fingerprinting, an Optimized Resource for Short Tandem Repeat Profile AuthenticationAlessio Somaschini, Roberta Bosotti, Nadia Amboldi et al.|Genetic Testing and Molecular Biomarkers|2013Cited by 14
Data from Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and BrachyuryPaola Magnaghi, Antonella Isacchi, Barbara Salom et al.|Unknown|2023Cited by 0